Solid-Tumour CAR-Therapy Phase I Study Design Strategy

With competition for patients, targets and differentiation intensifying, Phase I protocols must do more than establish safety. They need to generate evidence that supports a clear go/no-go decision, demonstrates a competitive efficacy profile and creates a credible path towards later-stage development. Yet the analysis found that only a small number of solid-tumour CAR-Therapy programmes have successfully crossed the Phase I/II boundary.

This report turns Beacon’s comprehensive, granular and human-curated CAR-Therapy data into practical decision intelligence for protocol development. It explores the designs associated with successful progression, benchmarks emerging competitors and efficacy signals, and brings the findings together in a protocol-ready framework to help teams make faster, more confident and evidence-led decisions.

In this report, you’ll learn:

• A detailed view of the competitive landscape
• Analysis of the programmes that progressed beyond Phase I
• Target and indication-specific efficacy benchmarks
• Insights into endpoints, lymphodepletion, dose escalation, armoring, safety monitoring and combination strategies
• A practical decision framework and five-question checklist